

Confirmation Report - Memory Send

Date & Time: Oct-05-2004 04:36pm

Tel line : 650 857 0663

Machine ID : COOLEY GODWARD LLP

Job number : 125
Date & Time : Oct-05 04:35pm
To : 15712730632
Number of pages : 002
Start time : Oct-05 04:35pm
End time : Oct-05 04:36pm
Pages sent : 002
Status : OK
Job number : 125

*** SEND SUCCESSFUL ***

Attorney Docket No. TLK-030/01US
Serial No. 09/748,665
Page 1
PATENT

Attorney Docket No. TLK-030/01US

I hereby certify that this correspondence is being transmitted by facsimile addressed to Examiner Wang, Art Unit 1617, Facsimile Number 571-273-0632, at United States Patent and Trademark Office, Alexandria, VA 22313-1450 at 4:36PM on October 5, 2004.

By: Hanna Hachova
Hanna Hachova

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Richard Sportman et al.

Serial No.: 09/748,665

Examiner: Wang, S.

Confirmation No.: 8219

Art Unit: 1617

Filed: December 21, 2000

For: NONPEPTIDE INSULIN RECEPTOR AGONISTS

Mail Stop AP
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER TO EXAMINER

At the request of Examiner Wang during our conversation on October 1, 2004, a clean version of claim 27 of the previous amendment (without underlining and bracketing) is being provided herewith. The Examiner indicated he had sent out a new office action detailing the MPEP requirements for a new declaration. As the inventors are no longer at Telik, Inc., a declaration will be provided as soon as the signatures from the inventors are obtained. This communication is being sent to fax number 571-273-0632 at the request of Examiner Wang.

The Commissioner is hereby authorized to charge any appropriate fee under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. (PA) 03-3117 or (RE) 50-1283.

Dated: 5 Oct. 2004

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
TMM:hh

Respectfully submitted,
COOLEY GODWARD LLP

By: Tom M. Moran
Tom M. Moran
Reg. No. 26,314

050441 v3/pa
ML15031.doc

Attorney Docket No. TLIK-030/01US
Serial No. 09/748,665
Page 1
PATENT

Attorney Docket No. TLIK-030/01US

I hereby certify that this correspondence is being transmitted by facsimile addressed to Examiner Wang, Art Unit 1617, Facsimile Number 571-273-0632, at United States Patent and Trademark Office, Alexandria, VA 22313-1450 at 4:25 PM on October 5, 2004.

By: Hanna Hacham
Hanna Hacham

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Richard Sportsman et al.

Serial No.: 09/748,665

Examiner: Wang, S.

Confirmation No.: 8219

Art Unit: 1617

Filed: December 21, 2000

For: **NONPEPTIDE INSULIN RECEPTOR AGONISTS**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER TO EXAMINER

At the request of Examiner Wang during our conversation on October 1, 2004, a clean version of claim 27 of the previous amendment (without underlining and bracketing) is being provided herewith. The Examiner indicated he had sent out a new office action detailing the MPEP requirements for a new declaration. As the inventors are no longer at Telik, Inc., a declaration will be provided as soon as the signatures from the Inventors are obtained. This communication is being sent to fax number 571-273-0632 at the request of Examiner Wang.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. (PA) 03-3117 or (RE) 50-1283.

Dated: 5 Oct. 2004

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
TMM/vhh

Respectfully submitted,
COOLEY GODWARD LLP

By: Tom M. Moran
Tom M. Moran
Reg. No. 26,314


680441 v2/PA
#L15021.DOC

Attorney Document No. TLIK-030/01US
Serial No. 09/748,665
Page 2

IN THE CLAIMS:

26. Cancelled

27. (amended) A method to lower blood glucose in a diabetic subject comprising administering to the subject a blood glucose-lowering effective amount of the compound of the formula



28. Cancelled